Compare AbbVie Inc (ABBV) vs Global X Copper Miners ETF (COPX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Global X Copper Miners ETF — how do they compare? AbbVie Inc trades at $253.74 (market cap $449.91B), while Global X Copper Miners ETF trades at $72.69. The key difference: AbbVie Inc pays a 2.72% dividend while Global X Copper Miners ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Global X Copper Miners ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | COPX | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $261.07 | $95.70 |
52-Week Low | $184.85 | $42.75 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
COPX (Global X Copper Miners ETF) trades at $78.48, up 2.39% with a bullish technical signal despite mixed moving averages. The ETF provides diversified exposure to copper mining companies benefiting from AI-driven copper demand growth. Recent news highlights copper's structural deficit and AI infrastructure needs as key catalysts. Technical indicators show RSI_12 at 24.51 (buy signal) while ADX suggests strong trend momentum.
Outlook remains positive given copper's essential role in AI infrastructure and electrification trends. Key risks include copper price volatility and supply chain constraints. The ETF offers leveraged exposure to copper prices through mining equities, with support at $76 and resistance at $79-80 levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →
